Pregnane X receptor (PXR) transactivation and binding assays have been developed into high-throughput assays, which are robust and reproducible (Z′ > 0.5). For most compounds, there was a good correlation between the results of the transactivation and binding assays. EC 50 values of compounds in the transactivation assay correlated reasonably well with their IC 50 values in the binding assay. However, there were discrepancies with some compounds showing high binding affinity in the binding assay translated into low transactivation. The most likely cause for these discrepancies was an agonistdependent relationship between binding affinity and transactivation response. In general, compounds that bound to human PXR and transactivated PXR tended to be large hydrophobic molecules. (Journal of Biomolecular Screening 2004:533-540) 
INTRODUCTION

P
REGNANE X RECEPTOR (PXR) is a nuclear hormone receptor principally responsible for the induction of cytochrome P450 (CYP)3A4, which plays a major role in metabolizing many clinically prescribed drugs. It is well known that the induction of CYP3A4 can cause drug-drug interaction by increasing the metabolic clearance of coadministered CYP3A4 substrates. 1, 2 Characterizing the induction potential of discovery or development drug candidates for this liability has become an important screen throughout the pharmaceutical industry.
Historically, primary cultures of human hepatocytes have been used to screen for CYP inducers. 3, 4 However, due to the laborious nature and limited availability of human hepatocytes, other more routine assays have been developed. Previously, Jones et al. described development of a SPA-based PXR binding assay in a 96-well format to evaluate CYP3A4 induction potential. 5 In our report, this assay was miniaturized to a 384-well format with some modification to improve efficiency. Previously, 2 PXR transactivation reporter assays have been described, one based on chloramphenicol acetyltransferase (CAT) as the reporter in a 96-well format 6 and another based on luciferase as the reporter in a 6-well format. 7 In both assays, transient-transfection was performed in individual wells, which was not readily adaptable to automated liquid handling equipment. As a reporter enzyme, CAT detection requires the use of a radiochemical and was not homogenous, whereas luciferase detection is nonradioactive and homogenous. Because homogenous detection can be easily adapted to high throughput, luciferase was chosen for the assay described herein. With the current assay, the transient transfection was performed in cell culture flasks prior to dispensing into the wells of a 384-well plate. Not only was this procedure compatible with the automated liquid handling equipment, it also reduced the variability of the assay and increased the throughput. Finally, a comparison of results between our binding and transactivation assays is discussed and differences between the assays are noted, as well as a characterization of the physicochemical properties of PXR binders and transactivators.
MATERIALS AND METHODS
Materials
Cell culture medium DMEM, Lipofectamine 2000, PBS, trypsin-EDTA (0.25%), and penicillin-streptomycin were purchased from GIBCO/Invitrogen (Carlsbad, CA). Charcoal/ dextran-treated fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT). HepG2 cells were obtained from ATCC (Manassas, VA). Human PXR-pcDNA3 and luciferase reporter containing Cyp3A4 promoter, Cyp3A-Luc, were generated as described previously. 8 Black standard 384-well plates were purchased from BD Biosciences (Lexington, KY), and white standard 384-well plates were purchased from Packard/PerkinElmer (Boston, MA Specifically biotinylated PXR-LBD (ligand binding domain) was prepared similarly to that previously described, 5 but with the following modifications. The DNA sequence encoding amino acids 130-434 of human PXR (RefSeq NM_003889 and NP_003880) was cloned using PCR via 5′ NdeI and 3′ EcoRI sites added in the PCR primers into a modified pET28a (Novagen, Madison, WI) expression vector containing a specific biotinylation sequence (LNDIFEAQKIEWHEDTG) 9 inserted before the NdeI site. Thus, PXR(130-434) was expressed with the following additional amino acids as an N-terminal tag: MGSSHHHHHH SSGLVPRGSH SLNDIFEAQK IEWHEDTGHM. A second expression vector, pCOT7/FLAG-SRC1-BirA, was created that expresses both an 88-amino acid fragment of the co-activator SRC-1 (amino acids 623-710, RefSeq NM_003743 and NP_003734) and E. coli biotin ligase (BirA, RefSeq M10123), both under control of a T7 promoter but with separate ribosome binding sites. The SRC1 fragment was expressed with N-terminal hexahistidine and FLAG tags, and the biotin ligase was untagged. The pCOT7 backbone was based on the pPROTet vector (BD Biosciences Clontech, Palo Alto, CA), which was modified by replacing the Tet promoter and multicloning site with the T7 promoter region from pET23a and a custom multiple cloning site. Competent BL21(DE3) E. coli cells (Novagen, Madison, WI) were co-transformed with both plasmids and selected overnight in LB media containing 30 µg/mL kanamycin and 30 µg/mL chloramphenicol (Sigma, St. Louis, MO). Expression was performed in minimal media supplemented with casamino acids and trace minerals, also containing both antibiotics at the concentrations indicated above. Cultures were grown to OD 600 at 0.6, chilled on ice for 30 min, induced by addition of 0.4 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) and 50 µM biotin (Sigma, St. Louis, MO), and incubated for 16 hours at 20°C. An approximately 2:1 mixture (determined by RP-HPLC) of His-FLAG-SRC-1(623-710) and singly and specifically biotinylated His-AviTag-PXR (130-434) was purified from cell lysate by Niaffinity chromatography and stored in aliquots at -70°C.
Transactivation assay
The protocol of Luo et al. was followed with some modification. 8 The culture of HepG2 cells was performed in gelatin-coated T175 flasks using DMEM containing 10% charcoal/dextrantreated FBS. The transfection mixture contained 1 µg/mL of PXRpcDNA3 plasmid DNA, 20 µg/mL of Cyp3A-Luc plasmid DNA, 90 µL/mL of Lipofectamine 2000, and serum-free medium. After incubating at room temperature for 20 min, the transfection mixture (1 mL per flask) was applied to the cells in fresh medium (20 mL per flask) and the flasks were incubated at 37°C (5% CO 2 ) overnight.
Cells in each flask were washed with PBS and trypsinized in 5 ml of Trypsin-EDTA (0.25%) for 10 min at 37°C. Then the flasks were tapped vigorously and the cells were pipetted up and down to break up aggregates. After the addition of 5 mL of DMEM containing 10% charcoal/dextran-treated FBS, the entire mixture was transferred to conical tubes and allowed to settle for 45 seconds, and the supernatant was withdrawn to remove cell aggregates and debris. The supernatant was then centrifuged at 1500 RPM for 4 min and the subsequent supernatant was discarded. The cell pellets were resuspended in 10 mL of DMEM containing 5% charcoal/ dextran-treated FBS and penicillin-streptomycin (100 units/mL penicillin and 100 µg/mL streptomycin). The cells were then counted and diluted to 0.44 million cells/ml. Forty-five microliters of cell mixture was added to each well of a black standard 384-well plate with 5 µL of test compound dissolved in DMSO-water (5% DMSO). The plates were incubated at 37°C (5% CO 2 ) overnight before 25 µL of luciferase substrate (Steady-Glo, Promega) was added to each well. After 30 min, the plates were read on a Packard Topcount plate reader. Studies were performed to show that the signal was stable up to 2 h. Rifampicin (10 µM), a well-known agonist of PXR, was included in each plate as an internal standard and positive control. The data were then expressed as percent activation (%Act):
where the total signal was the signal from the 10 µM rifampicin and the blank signal was from the DMSO vehicle. The compounds were tested either at a single-concentration, where the %Act at that concentration was reported, or at 10 concentrations (100 µM -5 nM, 1-to-3 serial dilution), where the maximum percent activation (Max %Act) observed in that concentration range and the EC 50 (the concentration at 50% of Max %Act) were reported. Due to potential cytotoxicity and aqueous solubility issues, Max %Act was not always at the highest concentration. EC 50 values were determined only for compounds that showed greater than 50% activation.
Curve-fitting software, XL-Fit (IDBS, Inc.) was used to generate EC 50 values.
Binding assay
The protocol of Jones et al. was followed with some modification. 5 The assay was carried out in 384-well white plates in total volume of 50 µL per well. Each well contained 50 mM Tris (pH 8), 50 mM KCl, 1 mM EDTA, 1 mM CHAPS, 1 mM DTT, 0.5% DMSO, 30 nM [ where the blank signal was the signal from the 10 µM SR12813 (cold ligand) and the total signal was from the DMSO vehicle. Compounds were tested either at a single concentration, where the %Inh at that concentration was reported, or at 10 concentrations (100 µM -5 nM, 1-to-3 serial dilution), where the maximum percent inhibition (Max %Inh) observed in that concentration range and the IC 50 (the concentration at 50% between the total and blank signals) were reported. Maximum %Inh was always at the highest concentration, 100 µM. IC 50 values were determined only for compounds that showed greater than 50% inhibition. Curve-fitting software, XL-Fit (IDBS, Inc.), was used to generate IC 50 values.
Cytotoxicity assay
HepG2 cells were processed as described in the "Transactivation Assay" section. Five microliters of test compound in DMSO-water (5% DMSO) was added to each well of black standard 384-well plates, followed by 45 µL of harvested cells (0.44 million cells/mL) and 5 µL of Alamar Blue. The plates were incubated at 37°C (5% CO 2 ) overnight before reading on an LJL plate reader in fluorescence mode (Ex: 535 nm, Em: 590 nm).
RESULTS AND DISCUSSION
Development and validation of high-throughput transactivation assay
The original transactivation assay, although resulting in a significant fold increase in signal (15-fold) using the standard agonist rifampicin (10 µM), exhibited extremely high signal variability, resulting in a negative Z′. Z′ is a statistical parameter used to evaluate the quality and reproducibility of assays; a good assay generally has a Z′ value ≥ 0.5.
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After testing several assay conditions, we improved the Z′ to 0.49-0.61 by employing certain conditions in the cell culture and assay conditions, which included gelatin-coated flasks to improve the attachment during cell culture; transient transfection was performed in cell culture flasks before dispensing into individual wells (whereas in previously published protocols, 6, 7 the transient-transfection was performed in individual wells); after harvest, the cell suspension was allowed to settle for 45 seconds and only the supernatant was withdrawn thereby removing cell aggregates and debris; black 384-well plates were used to eliminate well-to-well signal cross-talk; plates were sealed after the addition of luciferase substrate to increase the lifetime of the signal.
The assay statistics of 6 plates tested on 3 separate days are summarized in Table 1 for the final version of the assay. In addition, the PXR transactivation assay was tested with 17 drugs with known effects on CYP3A4 induction. Although there was run-torun variation of absolute signal intensity possibly due to the variation in transfection efficiency in each run, the results after normalization with the internal control (10 µM rifampicin) were found to be reproducible with regard to both Max %Act and EC 50 (Fig. 1A,  B) . Published results of 17 drugs, comprising strong, weak, and noninducers of CYP3A4 2, [5] [6] [7] [8] [11] [12] [13] correlated well with present findings (Fig. 1A) . After taking certain factors, such as CYP3A4 inhibition, into consideration, our results and the in vivo results from primary cultures of human hepatocytes were in general agreement. 5, 8, 11 
Development and validation of high-throughput binding assay
To determine the K d of [ 3 H] SR12813 for human PXR, different amounts of radioligand were added to the reaction containing 28 nM of receptor. By using nonlinear regression and the quadratic binding equation, which avoids the assumption that the free concentrations of ligand and receptor are the same as the total concentrations (see appendix), the K d was found to be 87 ± 7.6 nM in 3 replicate experiments (Fig. 2) . As a general guideline of receptor assay design, the concentrations of ligand and receptor are kept below K d so that IC 50 will not be significantly above K i , which causes underestimate of potency. However, if the concentrations of receptor and ligand are too low, the signal window will be too narrow. Based on the K d , the optimal concentrations of PXR receptor (70 nM) and radioligand (30 nM) were selected, so that the signal window between the total and background was maximized while maintaining a reasonable relationship between IC 50 and K i . The concentration of radioligand was kept low to avoid high background because the free radioligand is not removed in SPA assays. Under these conditions, the free ligand still accounts for the majority (60%) of total ligand. No assumptions were made that the free concentration of the ligand was similar to the total concentration in any of data processing. Table 2 shows the summary of assay statistics, where Z′ is approximately 0.58 for 6 plates tested on 3 separate days. We also employed the PXR binding assay to evaluate the same 17 drugs as in the transactivation assay. The assay results were shown to be reproducible for both Max %Inh and IC 50 (Fig. 3A,B) . In general, there was an agreement between the results of the transactivation and binding assays, though there was some discrepancy, which will be discussed later (Fig. 1A,B and 3A,B) . Results obtained from a previous reported PXR binding assay 5 correlated well with the present findings (Fig. 3A) .
Correlation of 2 assays against compounds randomly selected from a chemical library
A set of 616 compounds were randomly selected to represent large physicochemical diversity. Both PXR transactivation and binding assays were performed at 10 µM in duplicate for each of the 616 compounds. The average %Inh (binding) versus %Act (transactivation) of duplicate is plotted in Figure 4 , and clearly quadrants by using 40% as the cutoff value (40% was selected because all strong agonists are greater than this value in Figures 1A  and 3A) . Compounds in quadrant A (8% of compounds) demonstrated both high binding and transactivation, and represented potential CYP3A4 inducers; compounds in quadrant B (9%) demonstrated high binding but low transactivation (representing compounds that bound but did not result in significant transactivation); compounds in quadrant C (82%) were low in both assays; compounds in quadrant D (1%) demonstrated significant transactivation but low binding. Compounds in quadrant D only represented a minor population, which were all very close to the center of the 4 quadrants, indicating that they are not much different from the other 3 quadrants. Interestingly, in quadrant C we noticed that only after binding had reached a certain level (~30%-40% inhibition) did significant transactivation occur.
The compounds in quadrant B (high binding to PXR without resulting in significant transactivation) were of interest and mer-
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Journal of Biomolecular Screening 9(6); 2004 www.sbsonline.org 537 A B ited further investigation. The fundamental reason for this phenomenon lay in the mechanism of agonist-receptor activation. It has been well known that there is not always a linear correlation between the binding affinity and the downstream response generated by the binding, and this correlation depends on the conformational change of the receptor caused by the inducer. Therefore, some compounds may have strong binding but will not necessarily translate this binding into strong transactivation. 14 Other reasons for compounds appearing in quadrant B may include compounds that are antagonists of PXR rather than agonists; compounds that cause assay interferences, for example, in the binding assay, some compounds may quench the SPA signal, therefore appearing as false positives; in the transactivation assay, some compounds may be inhibitors of the reporter enzyme (luciferase), signal quenchers, cytotoxic compounds, or compounds with cell-permeability issues. In testing the 616 compounds at 10 µM in the binding assay, we found no cases of signal quenching. In the transactivation assay, 10 µM of rifampicin was added before the transactivation step to detect antagonists, inhibitors of luciferase, or signal quenchers by measuring signal decrease. We found only 14% of compounds in quadrant B significantly reduced the signal (> 40%), which may indicate antagonists, inhibitors of luciferase, or signal quenchers. Tested at 10 µM in the cytotoxicity assay, none of the compounds were found to be cytotoxic, though we noticed cytotoxic compounds at higher concentration. Unfortunately, we did not have access to an appropriate assay to test permeability of the 616 compounds for HepG2 cells.
An important characteristic of pharmaceutical compounds is potency, which is measured as EC 50 in the transactivation assay and IC 50 in the binding assay. 15 Only for compounds in quadrant A (Fig. 4) , which showed strong activity in the 2 assays, could both EC 50 and IC 50 be accurately determined. Thirty-two compounds in quadrant A for which enough quantity could be retrieved from the compound library were tested in both assays at 10 concentrations to study the correlation of potency in both assays. Figure 5 shows that EC 50 and IC 50 were reasonably correlated (R 2 = 0.65) with compounds having high EC 50 values tending to have high IC 50 values. These data suggest that when compound binding has been shown to result in transactivation, the binding assay has utility in driving SAR (structure-activity relationship). Although the transactivation assay directly measures the compound's ability to transactivate, results can be affected by a compound's cell permeability or lack of cell permeability. Therefore, both assays have value for SAR and a decision on which assay to employ should be customized for individual chemotypes.
In addition, molecular properties, such as cLogP and molecular weight, of the strong transactivators (%Act > 50%) in quadrant A (Fig. 4) , strong binders (%Inh > 50% but %Act < 30%) in quadrant B, and negative compounds (both %Act and %Inh < 30%) in quadrant C were studied (Fig. 6 ). Daylight software from Chemical Information Systems, Inc., was used for cLogP calculation. The strong agonists and binders in quadrants A and B generally have higher values of cLogP and molecular weight (MW) than the negative compounds in quadrant C, and the difference is statistically significant (Tukey's test, 16 P < 0.0001); however, there is no statistical difference between strong agonists in quadrant A and strong binders in quadrant B (Tukey's test, P = 0.99). According to studies of the 3-dimensional structure of human PXR by x-ray crystallography, the binding cavity of human PXR is very hydrophobic and larger than many other nuclear receptors, and may be expandable upon binding of large ligands, supporting our hypothesis of increased cLogP and MW for active compounds. 17, 18 Moreover, the binding site of PXR can accommodate structurally diverse ligands in contrast to other nuclear receptors, which is understandable because PXR upregulates defense against xenobiotics. This may explain the high hit rate (17% in the binding assay and 8% in the transactivation assay) of the 616 compounds randomly selected from a chemical library.
CONCLUSION
In this study, high-throughput PXR transactivation and binding assays have been developed in which the assay results have been shown to be reproducible. Moreover, a reasonable relationship exists between EC 50 in the transactivation assay and IC 50 in the binding assay (R ancy is the agonist-dependent relationship between binding affinity and transactivation response; also lack of cell-permeability as a possible cause can not be excluded. Analysis of the cLogP and molecular weight of 616 random library compounds indicates that human PXR binders and inducers are likely to be large hydrophobic molecules. By using the quadratic binding equation, the assumption that the free concentrations of ligand and receptor are the same as the total concentrations is not needed.
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